Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

OBJECTIVE: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. METHODS: National multicenter, non-controlled, open-label registry study o...

Descripción completa

Detalles Bibliográficos
Autores: Fernández Díaz, Carlos, Loricera García, Javier, Castañeda, Santos, López Mejías, Raquel, Ojeda Garcia, Clara, Olivé, Alejandro, Rodríguez Muguruza, Samantha, Carreira, Patricia E., Pérez Sandoval, Trinidad, Retuerto, Miriam, Cervantes Pérez, Evelin C., Flores Robles, Bryan J., Hernández Cruz, Blanca, Urruticoechea, Ana, González Vela, María del Carmen, Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462, Palmou Fontana, Natalia, Hernández Hernández, José Luis, González-Gay Mantecón, Miguel Ángel, Blanco Alonso, Ricardo|||0000-0003-2344-2285
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/14431
Acceso en línea:http://hdl.handle.net/10902/14431
Access Level:acceso abierto
Palabra clave:Rheumatoid Arthritis
Interstitial Lung Disease
Biologics
Abatacept
Descripción
Sumario:OBJECTIVE: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. METHODS: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. RESULTS: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63.2 ± 9.8 years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients the development of ILD was closely related to the administration of synthetic or biologic disease modifying anti-rheumatic drugs. After a follow-up of 9.4 ± 3.2 months, two-thirds of patients remained stable whereas one-quarter experienced improvement in the Modified Medical Research Council scale. At that time forced vital capacity remained stable in almost two-thirds of patents and improved in one out of five patients assessed. Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed. At 12 months, 50% of the 22 patients in whom chest HRCT scan was performed due persistence of respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to adverse events. CONCLUSION: ABA appears to be an effective in RA-associated ILD.

Similares en LA Referencia